Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)

NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)

US Patent 9475773 · Granted Oct 25, 2016

Estimated economic value: $34,149,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and use2024
Allogeneic cell therapy of B cell malignancies using genetically engineered T ce2022
Methods for treating IL-6 mediated inflammation without immunosuppression2022
Treatment of existing left ventricular heart failure2021
Cell populations which co-express CD49c and CD902019
Cell populations which co-express CD49c and CD902018
Cell populations which co-express CD49c and CD902018
Cell populations which co-express CD49c and CD902013
Prevention and treatment of degenerative diseases by glutathione and phase II de2004